Japanese iPS cell pioneer and US venture clear the air through patent alliance
This article was originally published in Scrip
Executive Summary
Two global leaders in induced pluripotent stem (iPS) cell technology have combined their intellectual property (IP) with the dual aims of speeding up its practical therapeutic application and avoiding a potential clash of patents.